Status:
COMPLETED
Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg
Lead Sponsor:
Chong Kun Dang Pharmaceutical
Conditions:
Hypercholesterolemia
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
This study was designed to compare the mean percent change of LDL-C between Lipilou® 10mg and 20mg group after 12 weeks of treatment.
Eligibility Criteria
Inclusion
- Patients who had hypercholesterolemia with high risk, according to the 2015 Korean guidelines for managing dyslipidemia.
Exclusion
- Patients with uncontrolled diabetes mellitus, uncontrolled hypertension, thyroid dysfunction.
- Patients who are legally unable to participate in clinical trials or who are unable to participate in clinical trials based on investigator's decision.
Key Trial Info
Start Date :
October 11 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2019
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04511000
Start Date
October 11 2017
End Date
May 20 2019
Last Update
August 12 2020
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Korea University Ansan Hospital
Ansan, South Korea
2
Sejong General Hospital
Bucheon-si, South Korea
3
Dong-A University Hospital
Busan, South Korea
4
Inje University Ilsan Paik Hospital
Goyang, South Korea